Price Crosses Moving Average
|Bid||7.11 x 900|
|Ask||7.25 x 1000|
|Day's Range||7.01 - 7.39|
|52 Week Range||1.27 - 19.20|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SHELTON, CT / ACCESSWIRE / June 30, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has been added to the Russell Microcap® Index effective after the U.S. markets opened yesterday, Monday, June 29, 2020. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
SHELTON, CT / ACCESSWIRE / June 23, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its third quarter of financial year 2020 with the Securities and Exchange Commission. The Company had requested a COVID-19-related extension to file the quarterly report. The Company reported that it had approximately $6.44 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.14M excluding a recent mortgage (described below), as of March 31, 2020, the end of the reporting period.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) (announced a positive readout for the Phase 1 study of KIT inhibitor CDX-0159) * Enochian Biosciences Inc (NASDAQ: ENOB) (moved on positive outcome from a preliminary FDA meeting regarding its HIV treatment candidate that could lead to pre-IND filing) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Phathom Pharmaceuticals Inc (NASDAQ: PHAT) * Replimune Group Inc (NASDAQ: REPL) * Sarepta Therapeutics Inc (NASDAQ: SRPT) (announced positive results from a study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zynex Inc. (NASDAQ: ZYXI)None of the NYSE- or Nasdaq-listed biopharma/medical diagnostics stocks hit 52-week lows Monday.Stocks In Focus Shockwave's IVL Procedure Gets CMS Code For Medicare Reimbursement Shockwave Medical Inc (NASDAQ: SWAV) said the Centers for Medicare & Medicaid Services issued new codes for intravascular lithotripsy, or IVL, procedures performed in peripheral arteries in both the hospital outpatient and inpatient settings.These outpatient and inpatient codes will go into effect July 1 and Oct. 1, respectively. Shockwave develops and markets IVL to treat complex calcified cardiovascular disease.Under these new codes, Medicare payment rates for IVL procedures performed in the hospital outpatient and inpatient settings are consistent with payment levels for other similar peripheral artery interventional procedures, Shockwave said.The stock added 9.13% to $49.11 in after-hours trading.Sanofi Announces Breast Cancer Combo Therapy Collaboration With Hong Kong's Alphamab Sanofi SA (NASDAQ: SNY) announced an agreement with Hong Kong-based biopharma Alphamab Oncology to establish a strategic collaboration to investigate the latter's KN026 in combination with Taxotere in HER2+ breast cancer. Sanofi is also granted an exclusivity period to negotiate the in-licensing of KN026, subject to the achievement of certain clinical milestones.KN026 is an anti-HER2 bispecific antibody that has shown promising preliminary efficacy and excellent safety profile in late-stage breast cancer patients who have failed multiple treatments in China.Soleno Says Late-Stage Study Of Genetic Disorder Drug Fails To Meet Primary Goal Soleno Therapeutics Inc (NASDAQ: SLNO) said its Phase 3 trial evaluating once-daily Diazoxide Choline Controlled Release, or DCCR, tablets for patients with Prader-Willi Syndrome did not meet its primary endpoint of change from baseline in hyperphagia.The company, however, said top-line results showed significant positive changes in two of the three key secondary points. It also said interim analysis of the ongoing extension study showed further reductions in hyperphagia of 48% after six months of DCCR treatment.The stock was down 48.15% at $1.68 premarket Tuesday. See also: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage NanoViricides' Coronavirus Candidates Found Superior To Remdesivir In Animal Models NanoViricides Inc (NYSE: NNVC) said it has signed a memorandum of understanding with respect to antiviral treatments for coronavirus-derived human infections with TheraCour Pharma. The MoU specifically provides a limited, exclusive license to all R&D toward human clinical trials. NanoViricides said it intends to retain an independent consultant for the evaluation of the assets in order to develop the full license agreement. The company said the broad-spectrum anti-coronavirus drug candidates that it is developing showed strong effectiveness in an animal model of human coronavirus disease, potentially superior to remdesivir in this particular model.The company cautioned that no conclusions to that effect can be drawn with the limited dataset. NanoViricides said prior to filing for human clinical trials, it plans on conducting studies to further determine the effectiveness against SARS-CoV-2, perform drug development studies for safety/toxicology and request a pre-IND Meeting with the FDA for regulatory guidance.The stock was up 7.18% at $7.02 premarket. Agios Blood Disorder Drug Receives Orphan Desgination Agios Pharmaceuticals Inc (NASDAQ: AGIO) said the FDA granted an orphan drug designation to its first-in-class pyruvate kinase-R activator mitapivat for the treatment of patients with thalassemia.Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.The stock advanced 1.68% to $53.11 in after-hours trading.Global Blood To Seek Label Expansion For Sickle Cell Disease Drug Global Blood Therapeutics Inc (NASDAQ: GBT) said it plans to seek label expansion for the potential use of Oxbryta for the treatment of sickle cell disease in children ages 4-11 following a Type B meeting with the FDA.View more earnings on IBBIt is currently approved in the U.S. to treat SCD in adults and adolescents 12 and older.The stock gained 4.8% to $69 in after-hours trading.Ardelyz Appoints Justin Renz As CFO Ardelyx Inc (NASDAQ: ARDX) announced the appointment of biopharma industry veteran Justin Renz to the position of CFO.Erytech Pharma Reports Positive Preliminary Results For Leukemia Drug In an update on the ongoing Phase 2 trial of eryaspase in second-line acute lymphoblastic leukemia patients, Erytech Pharma SA (NASDAQ: ERYP) said the trial, which is being conducted at 22 clinical sites in the Nordic and Baltic countries of Europe, has reached its target enrollment of 50 patients. The company also said preliminary findings from the study suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients.Additionally, the addition of eryaspase to the combination chemotherapy was associated with an acceptable tolerability profile, enabling the majority of these patients to receive their fully intended courses of asparginase.Enzo Biochem Posts Q3 Loss Enzo Biochem, Inc.'s (NYSE: ENZ) third-quarter revenues fell 14% year-over-year to $16.9 million, dragged by a 28% reduction in accession volume due to factors related to the COVID-19 pandemic. The company reversed from a profit of 47 cents per share to a loss of 21 cents per share.The stock moved down 6.57% to $2.56 in after-hours trading.Offerings Cerecor Inc (NASDAQ: CERC) said it intends to offer for sale shares of its common stock in an underwritten public offering. All the shares are being offered by Cerecor.The stock retreated 9.94% to $2.90 in after-hours trading.Replimune priced its upsized public offering of 2.826 million shares at $23 per share. The company also said it priced the public offering of pre-funded warrants to purchase 1.523 million of its common stock at $22.999 per pre-funded warrant. The company expects to raise $100 million in aggregate gross proceeds. All the securities earmarked for the offering are sold by the company. The company expects the offering to close June 11.The stock was plunging 17.39% to $2.66 premarket. Retrophin Inc (NASDAQ: RTRX) priced its underwritten public offering of 6.5 million shares of its common stock at $15.50 per share for gross proceeds of about $100.8 million. All of the shares are being sold by the company. The offering is expected to close June 11.In after-hours trading, the stock fell 3.44% to $15.98.Fate Therapeutics Inc (NASDAQ: FATE) priced its underwritten public offering of 6.182 million shares of its common stock at $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. All shares of common stock to be sold in the offering are being offered by the company. The offering is expected to close on or about June 11.The stock rose 2.44% to $29 in after-hours trading.On The Radar Clinical Readouts, Presentations Novavax, Inc. (NASDAQ: NVAX) said its President of Research and Development Gregory Glenn will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital, discussing COVID-19 vaccines. The panel discussion is scheduled for 11:30 am.Related Link: Novavax Analyst Says DoD Funding Reflects Conviction In Platform, Ability To Deliver On Vaccine See more from Benzinga * 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SHELTON, CT / ACCESSWIRE / June 9, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reported today that it has signed a Memorandum of Understanding ("MoU") with respect to anti-viral treatments for coronavirus derived human infections (the "Field") with TheraCour Pharma, Inc. The MoU specifically provides a limited, exclusive license to all research and development in the Field for further research and development purposes towards human clinical trials. NanoViricides intends to retain an independent consultant for the evaluation of the assets in order to develop the full license agreement.
SHELTON, CT / ACCESSWIRE / May 26, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has raised $10.22 Million in gross proceeds from the sale of 1.4 million shares of common stock, and no warrants, at a price of $7.30 per share, in a previously announced registered direct offering (the "Offering"). The co-Placement Agents were paid a total cash fee of 8% of the gross proceeds, plus $75,000 for reimbursement of legal fees. The net proceeds to the Company were approximately $9.327 Million, after deducting placement agent fees and other costs.
SHELTON, CT / ACCESSWIRE / May 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of $7.30 per share, for aggregate gross proceeds of approximately $10.22 million, in a registered direct offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering.
SHELTON, CT / ACCESSWIRE / May 20, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. NanoViricides is developing an animal model for coronavirus infection using hCoV-NL63 as a surrogate for SARS-CoV-2, the virus that causes COVID-19 disease.
SHELTON, CT / ACCESSWIRE / May 18, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives from Indiana, has joined the Company's Board of Directors, effective May 15, 2020, as an independent director. Most recently, Mr. Rokita has been nominated by President Trump to the Board of Directors of the National Railroad Passenger Corporation (aka Amtrak), pending U.S. Senate Confirmation.
SHELTON, CT / ACCESSWIRE / May 12, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has developed drug candidates that have demonstrated very high anti-viral effectiveness in cell culture studies against multiple coronaviruses. Two of the tested nanoviricides drug candidates were highly effective in cell culture assays against multiple coronaviruses that infect humans.
SHELTON, CT / ACCESSWIRE / May 4, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has signed a Confidential Disclosure Agreement ("CDA") with a leading pharmaceutical company in the Asian region to explore collaborating on the Company's COVID-19 program. NanoViricides previously disclosed that it has already identified certain drug candidates that are active against multiple coronaviruses in cell culture studies. The Company intends to perform testing against SARS-CoV-2 (the virus that causes COVID-19 disease) and is in advanced discussions with at least two sites that have such capability.
SHELTON, CT / ACCESSWIRE / April 29, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that the Company's presentation with an update of its drug development programs for the treatment of Shingles and for COVID-19 made at the Planet MicroCap Showcase 2020 on April 22nd is now available for viewing. Anil R. Diwan, PhD, President and Executive Chairman of the Company, presented this Corporate Update. The Company has drug candidates that were highly successful in cell culture studies against multiple coronaviruses.
SHELTON, CN / ACCESSWIRE / April 21, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it will provide an update of its drug development programs for the treatment of Shingles and for COVID-19 when it presents an overview of the Company at the Planet MicroCap Showcase 2020 tomorrow, Wednesday, April 22 at 6:40 PM EST. Anil R. Diwan, PhD, President and Executive Chairman of the Company, will be presenting and answering questions from investors. One-on-one meetings will be scheduled and conducted via private, secure video conferencing through the conference event platform.
SHELTON, CT / ACCESSWIRE / April 13, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), states that its President, Dr. Anil R. Diwan was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading, multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. The interview took place remotely, with Dr. Diwan and key staff members at the Company's Shelton, CT headquarters, on March 27, 2020. A video transcript of the interview published by Proactive Investors is now available at https://youtu.be/CLfTNbHcMzU and on the Company's website at www.nanoviricides.com.
SHELTON, CT / ACCESSWIRE / April 6, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral drugs based on a novel, patented, nanomedicines platform, reports that U.S. Senator Richard Blumenthal visited the Company's facility in Shelton, Connecticut, on Tuesday, March 31, 2020. The Honorable Senator Blumenthal visited the Company to receive an update regarding the coronavirus (COVID-19) drug development program and to tour the cGMP-capable manufacturing facility.
The Company's Update on its Development of COVID-19 Drug Candidate is Promising Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company's research involves the use of a unique nanomedicine technology called nanoviricides -- agents designed to "fool" a virus into attaching to an antiviral nanomachine, in ...
SHELTON, CT / ACCESSWIRE / March 16, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. The Company has completed the synthesis of a number of nanoviricide drug candidates for testing in just a few weeks after identification of virus-binding ligands. This was possible because the Company is boot-strapping its efforts on the basis of its inventory of novel custom chemicals in hand.
With the Dow Jones and the S&P; 500 plummeting as a result of the coronavirus pandemic, a number of interesting micro-cap stocks have emerged as interesting bets Continue reading...
In an increasingly sickly looking market, Inovio Pharmaceuticals (NASDAQ:INO) has been resurrected from a dead-like experience with investors. The question is, can it last? Let's take a look at what's pumping life into shares and whether INO stock is worth buying in today's market.Source: Ascannio / Shutterstock.com It's not the cure for cancer. But on Wall Street and where the coronavirus from China is spreading a bearish pandemic among risk-assets, shares of Inovio are acting like the cure-all in the eyes of many investors. The stock rocketed higher by nearly 230% on the week on staggering record-breaking volume of roughly 587 million shares.But there's more to the rally in Inovio as well.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe obvious bullish interest has allowed Inovio to close in on a 13-year high. Shares have also moved into the double digits above $14 a share as of Friday's close and firmly into small-cap territory with a market valuation of $1.43 billion. Furthermore and in safer venues than those around the workplace cooler, on the Yahoo Finance message boards, INO stock has enjoyed a healthy surge in conversations totaling more than 21,000.Yep, investors are suddenly and very definitely interested in Inovio Pharmaceuticals.Not that the stock is alone in its rapid validation among today's investors. There's Enzo Biochem (NYSE:ENZ), Nanoviricides (NYSEAMERICAN:NNVC) and Vir Biotechnology (NASDAQ:VIR), a more recognizable larger-cap stock like Gilead Sciences (NASDAQ:GILD). There's also a host of other companies which have caught Wall Street's attention in recent weeks as a well-contained COVID-19 health problem has become a global health and financial crisis. * 10 Best Stocks to Buy and Hold Forever The driver (of course) behind each of these companies' strong rallies has been an arms race of sorts to help remedy or solve the coronavirus in one way or another. But right now, Inovio does stand apart from many of the other biotechs tackling this problem.While INO stock is still mired in red ink, Inovio is the only company with an existing phase 2 vaccine used for the MERS or Middle East Respiratory Syndrome coronavirus. It's a big advantage. Also, this past week, Inovio announced it's accelerating the timeline for development of its DNA-based vaccine to this combat this new strain of coronavirus. Management expects human trials for INO-4800 to commence in April. But is all of this priced in already? INO Stock Price Monthly Chart Source: Charts by TradingViewAside from the aforementioned street-grabbing stats, INO stock has made other strong inroads as well. Most importantly, last week's rally burst shares out of six-year long downtrend as shown on the provided monthly chart. But don't think for a second it's clear sailing from here for today's buyers of Inovio Pharmaceuticals.The strong buying in Inovio now has the stock challenging the 50% retracement level from its 2004 relative high. Shares have also pierced, but fallen back below its MERS-related high of $15.80 set in 2014. Also, Inovio is in an overbought position as evidenced by its price extension above the upper Bollinger Band and the stock's monthly stochastics.Ultimately, I'm not overly enthusiastic on Inovio's longer-term prospects. I'd also stress that given the company's weak financial position and shares' rise to price levels associated with its last run-in with Wall Street's sell-side during the MERS outbreak, the stock is highly speculative. But for investors that dare to see things differently, I'd definitely recommend using the options market and a limited-risk strategy for positioning.The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Ways to Diversify Your Portfolio at This Time of Crisis * 3 Cannabis Stocks That Are Ready to Run * 5 High-Yield Dividend Stocks With Great Buyback Programs The post Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio? appeared first on InvestorPlace.
The Company has been working on a drug candidate to address the COVID-19 and has made significant progress in this regard New York, New York--(Newsfile Corp. - March 5, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company has recently been in the news for being one of the few biotechnology companies that ...
Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.